LDH-A Negatively Regulates DMMR in Colorectal Cancer

Overview

Journal Cancer Sci

Specialty Oncology

Date 2021 Jun 10

PMID 34110068

Citations 11

Authors

Yongjie Zhang

Juan Li

Bo Wang

Ting Chen

Yun Chen

Wen Ma

Affiliations

Soon will be listed here.

Abstract

Although immune checkpoint inhibitors (ICIs) have achieved unprecedented success in dMMR tumors, pMMR tumors accounting for 85% of colorectal cancer (CRC) cases remain unresponsive. Lactate dehydrogenase A (LDH-A) is the rate-limiting enzyme that catalyzes the transformation of pyruvate to lactate in the process of glycolysis. We investigated the relationship between LDH-A and dMMR with the purpose of exploring the treatment strategy for pMMR CRC patients. We here show that LDH-A can promote the proliferation of dMMR and pMMR CRC cells by positively regulating MMR proteins both in vitro and in vivo. LDH-A inhibition can improve the efficacy of PD-1 blockade in a pMMR CRC xenograft model. A statistical analysis of 186 CRC specimens showed a significant correlation between LDH-A and dMMR status. Moreover, patients with both low LDH-A expression and dMMR exhibited better disease-free survival compared with patients with other combinations. The close correlation of LDH-A and dMMR may offer a promising therapeutic strategy in which the combination of LDH-A inhibitor and ICIs may improve the clinical benefit for pMMR CRC patients.

Citing Articles

Revisiting of Cancer Immunotherapy: Insight from the Dialogue between Glycolysis and PD-1/PD-L1 Axis in the Tumor Microenvironment.

Liu Q, Liu Z, Zhang X, Zeng A, Song L Int J Biol Sci. 2025; 21(3):1202-1221.

PMID: 39897050 PMC: 11781164. DOI: 10.7150/ijbs.104079.

A positive correlation between serum lactate dehydrogenase level and in-hospital mortality in ICU sepsis patients: evidence from two large databases.

Yu H, Yang Q, Qian Y, Luo S, Kong T, Yang G Eur J Med Res. 2024; 29(1):525.

PMID: 39487549 PMC: 11531135. DOI: 10.1186/s40001-024-02071-4.

Role of glucose metabolic reprogramming in colorectal cancer progression and drug resistance.

Qin R, Fan X, Huang Y, Chen S, Ding R, Yao Y Transl Oncol. 2024; 50():102156.

PMID: 39405607 PMC: 11736406. DOI: 10.1016/j.tranon.2024.102156.

Prognostic factors and prognostic model of non-metastatic clear cell renal cell carcinoma.

Liao J, Zhang S, Ding Z BMC Cancer. 2024; 24(1):1263.

PMID: 39390388 PMC: 11468267. DOI: 10.1186/s12885-024-12922-2.

Involvement of tumor immune microenvironment metabolic reprogramming in colorectal cancer progression, immune escape, and response to immunotherapy.

Nicolini A, Ferrari P Front Immunol. 2024; 15:1353787.

PMID: 39119332 PMC: 11306065. DOI: 10.3389/fimmu.2024.1353787.

References

Bendardaf R, Saheb Sharif-Askari F, Sharif-Askari N, Syrjanen K, Pyrhonen S . Patients with hMLH1 or/and hMSH2-deficient Metastatic Colorectal Cancer Are Associated with Reduced Levels of Vascular Endothelial Growth Factor-1 Expression and Higher Response Rate to Irinotecan-based Regimen. Anticancer Res. 2018; 38(11):6399-6404. DOI: 10.21873/anticanres.13000. View

Rizvi N, Hellmann M, Snyder A, Kvistborg P, Makarov V, Havel J . Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015; 348(6230):124-8. PMC: 4993154. DOI: 10.1126/science.aaa1348. View

Pages F, Mlecnik B, Marliot F, Bindea G, Ou F, Bifulco C . International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet. 2018; 391(10135):2128-2139. DOI: 10.1016/S0140-6736(18)30789-X. View

Mlecnik B, Bindea G, Angell H, Maby P, Angelova M, Tougeron D . Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability. Immunity. 2016; 44(3):698-711. DOI: 10.1016/j.immuni.2016.02.025. View

Ji R, Chasalow S, Wang L, Hamid O, Schmidt H, Cogswell J . An immune-active tumor microenvironment favors clinical response to ipilimumab. Cancer Immunol Immunother. 2011; 61(7):1019-31. PMC: 11028506. DOI: 10.1007/s00262-011-1172-6. View

Overman M, McDermott R, Leach J, Lonardi S, Lenz H, Morse M . Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 2017; 18(9):1182-1191. PMC: 6207072. DOI: 10.1016/S1470-2045(17)30422-9. View

Dunn G, Old L, Schreiber R . The three Es of cancer immunoediting. Annu Rev Immunol. 2004; 22:329-60. DOI: 10.1146/annurev.immunol.22.012703.104803. View

Yu J, Vodyanik M, Smuga-Otto K, Antosiewicz-Bourget J, Frane J, Tian S . Induced pluripotent stem cell lines derived from human somatic cells. Science. 2007; 318(5858):1917-20. DOI: 10.1126/science.1151526. View

Le D, Uram J, Wang H, Bartlett B, Kemberling H, Eyring A . PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015; 372(26):2509-20. PMC: 4481136. DOI: 10.1056/NEJMoa1500596. View

10.

Zhang Y, Li J, Wang B, Chen T, Chen Y, Ma W . LDH-A negatively regulates dMMR in colorectal cancer. Cancer Sci. 2021; 112(8):3050-3063. PMC: 8353898. DOI: 10.1111/cas.15020. View

11.

Rooney M, Shukla S, Wu C, Getz G, Hacohen N . Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell. 2015; 160(1-2):48-61. PMC: 4856474. DOI: 10.1016/j.cell.2014.12.033. View

12.

Vogelstein B, Papadopoulos N, Velculescu V, Zhou S, Diaz Jr L, Kinzler K . Cancer genome landscapes. Science. 2013; 339(6127):1546-58. PMC: 3749880. DOI: 10.1126/science.1235122. View

13.

Brand A, Singer K, Koehl G, Kolitzus M, Schoenhammer G, Thiel A . LDHA-Associated Lactic Acid Production Blunts Tumor Immunosurveillance by T and NK Cells. Cell Metab. 2016; 24(5):657-671. DOI: 10.1016/j.cmet.2016.08.011. View

14.

Zhang C, Lv J, Gong L, Yu L, Chen X, Zhou H . Role of Deficient Mismatch Repair in the Personalized Management of Colorectal Cancer. Int J Environ Res Public Health. 2016; 13(9). PMC: 5036725. DOI: 10.3390/ijerph13090892. View

15.

Scott K, Cleveland J . Lactate Wreaks Havoc on Tumor-Infiltrating T and NK Cells. Cell Metab. 2016; 24(5):649-650. DOI: 10.1016/j.cmet.2016.10.015. View

16.

Tumeh P, Harview C, Yearley J, Shintaku I, Taylor E, Robert L . PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014; 515(7528):568-71. PMC: 4246418. DOI: 10.1038/nature13954. View

17.

Herbst R, Soria J, Kowanetz M, Fine G, Hamid O, Gordon M . Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014; 515(7528):563-7. PMC: 4836193. DOI: 10.1038/nature14011. View

18.

Dillon P, Olson W, Czarkowski A, Petroni G, Smolkin M, Grosh W . A melanoma helper peptide vaccine increases Th1 cytokine production by leukocytes in peripheral blood and immunized lymph nodes. J Immunother Cancer. 2014; 2:23. PMC: 4131803. DOI: 10.1186/2051-1426-2-23. View

19.

Llosa N, Cruise M, Tam A, Wicks E, Hechenbleikner E, Taube J . The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov. 2014; 5(1):43-51. PMC: 4293246. DOI: 10.1158/2159-8290.CD-14-0863. View

20.

Kim R, Emi M, Tanabe K . Cancer immunoediting from immune surveillance to immune escape. Immunology. 2007; 121(1):1-14. PMC: 2265921. DOI: 10.1111/j.1365-2567.2007.02587.x. View